Chromosomal microarray analysis (CMA) has been used routinely in pediatric and prenatal
genetic diagnosis in clinical practice, but it has rarely been applied to miscarriage analysis …

OBJECTIVE: To report the full cohort of identifiable anomalies, regardless of known clinical
significance, in a large-scale cohort of postmiscarriage products-of-conception samples …

Background Chromosomal abnormality is one of the major cause of spontaneous abortion.
Most available guidelines suggest genetic testing after three miscarriages, which has been …

Objective To investigate the efficacy and outcomes of chromosomal microarray (CMA) in the
cytogenomic evaluation of products of conception (POC). Method Over a 42‐month period …

Purpose Chromosomal microarray analysis (CMA) is currently considered first-tier testing in
pediatric care and prenatal diagnosis owing to its high diagnostic sensitivity for …

Objective To evaluate the results of prenatal chromosomal microarray analysis (CMA) on>
1000 fetal samples referred for testing at our institution and to compare these data to …

Miscarriage is the spontaneous loss of an embryo or fetus before the 20th week of
pregnancy. Most miscarriages occur before the end of the first trimester (< 13 weeks) …

Objectives To determine the frequency of clinically significant chromosomal abnormalities
identified by chromosomal microarray in pregnancy losses at any gestational age and to …

Chromosomal microarray analysis (CMA) is performed either by array comparative genomic
hybridization or by using a single nucleotide polymorphism array. In the prenatal setting …

Chromosomal microarray analysis (CMA) assesses chromosomal copy number alterations
and affords higher resolution when compared with standard karyotype. This review provides …